Prospective evaluation of imipenem trough concentrations and clinical outcomes in critically ill patients
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag242 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Mia Madeleine Lidén und 7 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Department, Geneva University Hospitals and Faculty of Medicine, Rue Willy-Donzé 6, Geneva 1205, Switzerland. Hauptthemen laut MEDLINE: Imipenem, Critical Illness, Anti-Bacterial Agents, Bacterial Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Geneva University Hospital Research and Developpement.
Abstract (Originalsprache)
Background
Imipenem is a broad-spectrum antibiotic commonly used in critically ill patients, whose pharmacokinetic profile can be highly variable. While imipenem therapeutic drug monitoring (TDM) is being adopted increasingly, efficacy and toxicity plasma thresholds remain incompletely defined. Few studies have prospectively and systematically assessed imipenem concentrations in severely ill patients before clinical failure or toxicity events occur.
Methods
This prospective observational cohort study conducted at the University Hospitals of Geneva consecutively included all adult patients hospitalized for suspected or confirmed severe bacterial infections in the haematology, intermediate care and intensive care units whose clinicians prescribed imipenem. On inclusion, patients underwent imipenem plasma-concentration monitoring, with trough levels measured at steady state. We assessed the frequency of adverse events and clinical success over a 30-day period.
Results
Of 142 patients undergoing imipenem monitoring, 106 had trough levels drawn at steady state. The median trough concentration was 2.4 mg/L (IQR 1.2–4.0). Among all patients, adverse events occurred in 4.9% (7/142), while clinical success was achieved in 88/106 with trough levels (83%). No significant differences in trough levels were observed between patients with and without clinical success or with and without adverse events. Renal clearance had a significant impact on trough levels.
Conclusion
Prospective, universally applied imipenem monitoring reveals lower trough levels than previously described. Nonetheless, this cohort of critically ill and/or immunosuppressed patients still experienced high rates of clinical success, with few adverse events. While low trough concentrations did not predict failure, rare outlying higher concentrations (10–20 mg/L) also did not predict toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Paediatric Department, Geneva University Hospitals and Faculty of Medicine, Rue Willy-Donzé 6, Geneva 1205, Switzerland.
- Intensive Care Unit, Geneva University Hospitals, Rue Gabrielle Perret-Gentil 4, Geneva 1205, Switzerland.
- Centre for Clinical Research, Clinical Trials Unit, University Hospital and University of Geneva, Rue Gabrielle Perret-Gentil 4, Geneva 1205, Switzerland.
- Toxicology and Therapeutic Drug Monitoring Laboratory, Geneva University Hospitals, Rue Gabrielle Perret-Gentil 4, Geneva 1205, Switzerland.
- Infectious Disease Division, Geneva University Hospitals and Faculty of Medicine, Rue Gabrielle Perret-Gentil 4, Geneva 1205, Switzerland.
ORCID-Profile: Mia Madeleine Lidén
Förderung
- Geneva University Hospital Research and Developpement
Zitieren
APA
Lidén, M. M., Boroli, F., Von Dach, E., Lescuyer, P., Tonoli, D., Huttner, A., OPTIMAL TDM Study Group, & on behalf of (2026). Prospective evaluation of imipenem trough concentrations and clinical outcomes in critically ill patients. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag242
Vancouver
Lidén MM, Boroli F, Von Dach E, Lescuyer P, Tonoli D, Huttner A, et al. Prospective evaluation of imipenem trough concentrations and clinical outcomes in critically ill patients. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag242
BibTeX
@article{Lidn2026,
author = {Lidén, Mia Madeleine and Boroli, Filippo and Von Dach, Elodie and Lescuyer, Pierre and Tonoli, David and Huttner, Angela and OPTIMAL TDM Study Group, OPTIMAL TDM Study Group and on behalf of, on behalf of},
title = {Prospective evaluation of imipenem trough concentrations and clinical outcomes in critically ill patients},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag242}
}
EUVIMED